Zasocitinib Phase 3 Data Demonstrate Rapid, Durable Skin Clearance in Plaque Psoriasis

Late-breaking data presented at the 2026 American Academy of Dermatology Annual Meeting highlight the therapeutic potential of zasocitinib, an investigational oral agent for moderate to severe plaque psoriasis. In an interview, Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine and Dermatology Times’ editor in chief, and Chinweike Ukomadu, MD, PhD, therapeutic area head for GI and inflammation at Takeda Pharmaceuticals, outlined findings from 2 pivotal phase 3 trials.^1,2

The studies evaluated once-daily zasocitinib against both placebo and the active comparator apremilast in patients with moderate to severe plaque psoriasis. Co-primary endpoints included static Physician’s Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75 at week 16.

High Rates of Skin Clearance

Zasocitinib demonstrated robust efficacy across multiple clinically meaningful end points. Approximately 70% of patients achieved clear or nearly clear skin (sPGA 0/1), with a comparable proportion reaching PASI 90. Notably, stringent clearance end points were also met, with up to 49% of patients achieving sPGA 0 and 42% reaching PASI 100.

“These findings suggest that a convenient, once-daily oral therapy can deliver high levels of skin clearance,” Ukomadu said, emphasizing the clinical relevance of complete or near-complete resolution for patients.

Rapid Onset

A key differentiator of zasocitinib was its rapid onset of action. Separation from placebo was observed as early as week 4, emphasizing its potential for early disease control.

Quality-of-life improvements were also notable. By week 24, up to 60% of patients achieved Dermatology Life Quality Index (DLQI) scores of 0 or 1, indicating no impact of psoriasis on daily life.

“Patients want therapies that work quickly and meaningfully improve how they live,” Bunick noted, highlighting the alignment between clinical efficacy and patient-reported outcomes.

Consistent Safety Profile

The safety profile of zasocitinib in phase 3 was consistent with previously reported phase 2b data, with no new safety signals identified. This consistency supports continued confidence in the agent’s risk-benefit profile as it advances toward potential regulatory review.

Positioning in an Expanding Oral Therapeutic Landscape

As Bunick said, “the oral psoriasis treatment space is booming,” and zasocitinib may represent a meaningful addition. Its combination of convenience, rapid onset, and high clearance rates positions it as a potential alternative to both traditional systemic agents and injectable biologics.

Takeda is continuing efforts to advance zasocitinib toward regulatory submission, with the goal of expanding options for patients seeking non-injectable therapies for moderate to severe plaque psoriasis.

References

1. Gooderham M. Once-daily oral zasocitinib demonstrates rapid and reproducible skin clearance with a consistent safety profile in moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002). Presented at: 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, CO.
2. Takeda’s zasocitinib delivered rapid and durable skin clearance in a convenient once-daily pill, affirming promise to reshape psoriasis care. News release. Takeda. March 28, 2026. Accessed March 30, 2026. https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-phase3-clinical-trial-results/